Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 93,310,440
  • Shares Outstanding, K 1,647,430
  • Annual Sales, $ 19,427 M
  • Annual Income, $ 4,457 M
  • 36-Month Beta 1.19
  • Price/Sales 4.86
  • Price/Cash Flow 18.67
  • Price/Book 6.50

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.56 +9.85%
on 06/07/17
57.90 -2.18%
on 06/22/17
+2.43 (+4.48%)
since 05/23/17
3-Month
51.56 +9.85%
on 06/07/17
57.90 -2.18%
on 06/22/17
+0.87 (+1.56%)
since 03/23/17
52-Week
46.01 +23.10%
on 01/26/17
77.12 -26.56%
on 07/15/16
-16.00 (-22.03%)
since 06/23/16

Most Recent Stories

More News
Four-Year Follow-up with Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial

--The extended follow-up data is the longest of an Immuno-Oncology agent in relapsed/refractory multiple myeloma

BMY : 56.64 (-1.20%)
Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

NVO : 44.44 (+1.76%)
MRK : 66.16 (+0.21%)
NVS : 86.34 (unch)
SHPG : 172.98 (-1.11%)
RHHBY : 32.7600 (+1.42%)
BMY : 56.64 (-1.20%)
NEOS : 7.25 (-2.03%)
Global Cryptococcosis Market to Reach $6.7 Billion by 2025 - Analysis By Treatment Type & Geography

Research and Markets has announced the addition of the "Global Cryptococcosis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...

ABT : 49.08 (-0.39%)
ALPMF : 12.4900 (+1.20%)
NVS : 86.34 (unch)
PFE : 34.17 (+0.32%)
BMY : 56.64 (-1.20%)
Global Tinea Pedis Treatment Market to Grow at a CAGR of 3% by 2021 - Key Vendors are GSK, Exeltis USA, Valeant & Viamet Pharmaceuticals

Research and Markets has announced the addition of the "Global Tinea Pedis Treatment Market 2017-2021" report to their offering. The global tinea pedis treatment market to grow at a CAGR of 3.03% during...

AGN : 246.46 (-0.26%)
AMGN : 172.50 (-0.76%)
CELGZ : 1.14 (+1.79%)
BMY : 56.64 (-1.20%)
AVEO Reaches Enrollment Target in Pivotal Tivozanib Study

AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target

BAYRY : 136.3600 (+0.10%)
AVEO : 1.25 (+71.23%)
EXEL : 23.78 (-1.20%)
BMY : 56.64 (-1.20%)
S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017

S&P Dow Jones Indices ("S&P DJI") today announced preliminary results indicating that S&P 500® stock buybacks, or share repurchases, totaled $133.1 billion for Q1 2017. This is a 1.6% decrease from the...

CVS : 77.41 (+0.25%)
HUM : 238.42 (+0.60%)
AAPL : 146.28 (+0.45%)
C : 63.41 (-0.33%)
BAC : 22.82 (-0.48%)
JPM : 86.86 (-0.18%)
JNJ : 136.43 (+0.28%)
PFE : 34.17 (+0.32%)
BMY : 56.64 (-1.20%)
DIS : 104.36 (+0.13%)
AET : 152.10 (-0.58%)
MSFT : 71.21 (+1.35%)
WFC : 52.45 (-0.08%)
V : 95.58 (+1.73%)
PG : 89.42 (+0.44%)
SPGI : 146.70 (+0.91%)
ISRG : 948.94 (-0.55%)
GE : 27.57 (+0.07%)
AIG : 63.02 (-0.05%)
BA : 202.23 (+1.40%)
WMT : 74.84 (-0.90%)
Bristol-Myers Squibb Announces the Expiration of its Cash Tender Offer

Bristol-Myers Squibb Company (NYSE:BMY) announced today the expiration, as of 5:00 p.m., New York City time, on June 20, 2017, of its previously announced cash tender offer for any and all...

BMY : 56.64 (-1.20%)
Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth

Research and Markets has announced the addition of the "Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors...

JNJ : 136.43 (+0.28%)
LLY : 83.89 (-0.50%)
AMGN : 172.50 (-0.76%)
CELGZ : 1.14 (+1.79%)
BMY : 56.64 (-1.20%)
Global Head and Neck Cancer Treatment Market to Grow at a CAGR of 8% by 2021 - Key Vendors are Bristol-Myers Squibb, Eli Lilly, Merck & Pfizer

Research and Markets has announced the addition of the "Global Head and Neck Cancer Treatment Market 2017-2021" report to their offering. The global head & neck cancer treatment market to grow at a CAGR...

MRK : 66.16 (+0.21%)
LLY : 83.89 (-0.50%)
AMGN : 172.50 (-0.76%)
GSK : 44.29 (+0.29%)
BMY : 56.64 (-1.20%)
High Court ruling may hurt claims of talc link to cancer

ST. LOUIS (AP) — A Supreme Court ruling this week could have a "chilling effect" on the many lawsuits filed in St. Louis claiming talcum powder causes a deadly form of cancer in women, including cases...

JNJ : 136.43 (+0.28%)
BMY : 56.64 (-1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain;...

See More

Support & Resistance

2nd Resistance Point 57.87
1st Resistance Point 57.25
Last Price 56.64
1st Support Level 56.13
2nd Support Level 55.63

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.